Can weight return after stopping a GLP-1?

In two clinical trials, many people regained a large part of the weight they had lost after treatment was stopped. After one year off semaglutide, participants regained about two-thirds of their prior loss on average. Results varied, and the trials do not say what any one person will experience. Do not stop or change a prescribed medicine without talking to your clinician.

Sources checked against Europe PMC abstracts and FDA/DailyMed label text: Nov 17, 2026; full text not read for abstract-only claims (recheck on publication date)

Quick answer

In two clinical trials, many people regained a large part of the weight they had lost after treatment was stopped. After one year off semaglutide, participants regained about two-thirds of their prior loss on average. Results varied, and the trials do not say what any one person will experience. Do not stop or change a prescribed medicine without talking to your clinician.

What the trials found

Weight after stopping, two trials

Weight after stopping, two trials

Semaglutide (STEP 1 extension, 2022). STEP 1 gave 1,961 adults with obesity or overweight and no diabetes semaglutide 2.4 mg or placebo for 68 weeks, plus lifestyle intervention. At week 68, treatment and the lifestyle intervention were stopped. A follow-up extension, which was exploratory, assessed 327 participants for a further year. In the semaglutide group, mean weight loss was 17.3% at week 68. By week 120, participants had regained 11.6 percentage points of the lost weight, for a net loss of 5.6% from week 0. Placebo participants regained 1.9 percentage points, for a net loss of 0.1%. Cardiometabolic improvements seen at week 68 (for example in risk factors) mostly moved back toward baseline at week 120. Source: Wilding et al., Diabetes Obes Metab 2022.

Tirzepatide (SURMOUNT-4, JAMA 2024). In 783 adults with obesity or overweight and no diabetes, all started on tirzepatide (10 or 15 mg) for 36 weeks. Of 670 who completed this lead-in (mean weight reduction 20.9%), 335 were randomized to continue tirzepatide and 335 to switch to placebo for 52 weeks. From week 36 to week 88, mean weight change was -5.5% with continued tirzepatide and +14.0% with placebo. Source: Aronne et al., JAMA 2024.

The two trials used different medicines, designs and starting points, so their numbers should not be compared.

Why trial averages are not a prediction

  • Both are averages across groups; individual results vary.
  • The STEP 1 extension covered a subset of the original participants and its analyses were exploratory.
  • The trials ran for about a year after stopping or switching and cannot show what happens later.
  • They did not test what happens when people stop because of side effects, cost or supply, or when stopping is planned with lifestyle support or another treatment.

Talk with your clinician

Reasons for stopping (side effects, cost, supply, a goal reached), alternatives, and warning signs to watch should be planned with your clinician. This page gives no schedule or instructions for stopping.

Questions to bring:

  • Why do I want to stop, and what are the alternatives?
  • What follow-up and monitoring would be useful, and when?
  • What symptoms should make me contact the care team?
  • What should I track (weight, appetite, blood pressure, blood sugar if relevant)?
  • What does my product’s label or Medication Guide say about stopping or missed treatment?

For the exact instructions for your medicine, use your Medication Guide and prescribing information.

What this does not establish

These trials do not show that weight regain is inevitable, that every person regains the same amount, or that one medicine is better than another at keeping weight off. They do not say how long treatment should last for any person.

FAQs

What does evidence say about weight after stopping a GLP-1? In STEP 1’s extension, participants regained about two-thirds of their prior loss one year after stopping semaglutide. In SURMOUNT-4, people switched to placebo regained 14.0% on average over 52 weeks while those who continued tirzepatide lost a further 5.5%.

What information should I track or bring to the appointment? Weight over time, symptoms, other health measures your clinician follows, and your reasons for stopping.

Where can I find the instructions for my exact medicine? Your Medication Guide, the prescribing information and your care team.

Sources

  1. Wilding et al., Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension, Diabetes Obes Metab 2022
  2. Aronne et al., Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial, JAMA 2024